# Yposkesi breaks ground on second gene therapy plant in Genopole, France

Yposkesi, a French CMO owned by SK Inc., has begun construction of a second plant in Genopole, France, costing EUR 58 million. The facility will double production capacity and is expected to be completed by 2023.

- Type: New facility
- Announced: 2021-06-14
- Where: Genopole, France, France
- Value: $70.0M (58.0M EUR)
- Starts operating: 2023
- Status: under construction
- Capacity: 5,000 square meters
- Products: gene and cell therapy, gene vector production
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Yposkesi](https://endata.com/companies/55816.md)
- [SK디앤디](https://endata.com/companies/20456.md) (investor)

## Sources

- [pulse.mk.co.kr](https://pulse.mk.co.kr/news/english/9912976), 2021-06-15: "Yposkesi broke ground for its second factory that would cost 58 million euros ($70 million)."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.